Reckitt Benckiser’s Mead Johnson unit and Abbott Laboratories have been ordered to face a new trial in the US over ...

Reckitt Benckiser’s Mead Johnson unit and Abbott Laboratories have been ordered to face a new trial in the US over allegations their premature infant formula can cause a serious gut condition.

Reckitt has shown a medium-term uptrend since April 2024, outperforming peers, but litigation risks from Mead Johnson remain substantial, making the stock a hold. Reckitt's strategic focus on high ...

Reckitt Benckiser is continuing to assess options for its nutrition operations housing the Mead Johnson infant-formula business. After describing nutrition as “non-core” in July as part of a ...

In March 2024, a U.S. court in Illinois awarded $60 million in damages to a mother of a baby that died from necrotizing ...

Back in October, a jury found North Chicago-based Abbott and Reckitt’s formula subsidiary Mead Johnson not responsible for a ...

The stable outlook reflects Moody’s base case expectations that Reckitt’s gross debt/EBITDA leverage will stay at or below 2.5x, and that the company’s competitive position will continue to support ...

Infant formula makers Abbott and Reckitt saw their stocks decline Friday after a judge ruled plaintiffs could pursue a new ...

A Missouri judge has ordered Abbott Laboratories and Reckitt Benckiser unit Mead Johnson to face a new trial over allegations ...